Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

DUBLIN, Ireland, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc HZNP, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the compensation committee of its board of directors approved the grant on Dec. 1, 2017 of inducement restricted stock units for an aggregate of 112,552 ordinary shares and inducement stock options for an aggregate of 28,599 ordinary shares to 30 new employees.

Each restricted stock unit vests over four years, with 25 percent of the shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employee's continued service relationship with the Company.  Each restricted stock unit also is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.

Each stock option has an exercise price per share equal to $14.33, the fair market value on the grant date, and vests over four years, with 25 percent of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company.  Each stock option also has a 10-year term and is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.

The restricted stock units and stock options were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with NASDAQ Listing Rule 5635(c)(4).

About Horizon Pharma plc

Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs.  The Company markets 11 medicines through its orphan, rheumatology and primary care business units.  For more information, please visit www.horizonpharma.com.  Follow @HZNPplc on Twitter or view careers on our LinkedIn page.

Contacts:

Tina Ventura

Senior Vice President, Investor Relations

Investor-relations@horizonpharma.com

Ruth Venning

Executive Director, Investor Relations

Investor-relations@horizonpharma.com

U.S. Media Contact:

Geoffrey Curtis

Senior Vice President, Corporate Affairs and Chief Communications Officer

media@horizonpharma.com

Ireland Media Contact:

Ray Gordon

Gordon MRM 

ray@gordonmrm.ie